CenExel acquires ForCare to boost clinical research support
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

CenExel acquires ForCare to boost clinical research support

05 Aug 2021 (Last Updated August 5th, 2021 15:01)

CenExel FCR carries out Phase I to Phase IV clinical trials in chronic and acute conditions.

CenExel Clinical Research has acquired ForCare Clinical Research (CenExel FCR) to boost the support it provides for clinical research across a variety of therapeutic areas.

ForCare is a clinical research organisation with experienced principal investigators while CenExel offers medical and scientific support for designing and implementing clinical trials.

CenExel FCR performs Phase I-IV trials in chronic and acute conditions, specifically in dermatology.

In addition to dermatology, the deal bolsters CenExel’s clinical research support in immunology and multiple other therapeutic indications.

CenExel FCR is run by principal investigators who perform trials across dermatology, immunology and inflammatory disease, neurology and internal medicine areas.

The company will leverage the site network’s methods in different aspects such as centralised budgeting, business development and quality management.

Furthermore, CenExel FCR will collaborate with CenExel’s Centers of Excellence to further develop dermatology trials via cross-training and combination.

CenExel Clinical Research CEO Tom Wardle said: “The many strengths at CenExel FCR align perfectly with CenExel’s mission to be the leader in therapeutically focused clinical research.

“With this addition, CenExel now has the leading platform to conduct clinical trials in dermatology, CNS, vaccine and clinical pharmacology. This addition elevates our entire network.”

With the acquisition, the CenExel Centers of Excellence network expanded to ten clinical research facilities that focus on dermatology/immunology, neurology, vaccines, sleep studies and pain among others.

These facilities aid pharmaceutical sponsors in protocol development, study design and performing Phase I-IV trials for new medicines.

CenExel FCR chief operating officer Misty Sturges said: “CenExel FCR will keep exceeding enrolment expectations, preserving subject retention, reducing trial timelines, and delivering reproducible, quality data.

“We’re excited to see even faster study start-up and efficiencies by employing CenExel’s site network resources in our single-site and multi-site studies.”

Founded in 2018, CenExel created its Centers of Excellence in 2019 to execute Phase I-IV trials.